Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 1Solid Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 15Pemetrexed 15Cisplatin 12Nivolumab 9Carboplatin 8Ipilimumab 7tazemetostat 3fludarabine 3anetumab ravtansine 3Cyclophosphamide 3spartalizumab 2budigalimab 2belinostat 2atezolizumab 2amatuximab 2Vinorelbine 2Paclitaxel 2Gemcitabine 2Docetaxel 2venetoclax 1vandetanib 1trametinib 1tocilizumab 1tislelizumab 1sotorasib 1ruxolitinib 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma × CB-839 × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡